New drug trial hopes to shrink Hard-to-Treat cancers
NCT ID NCT06966024
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This early-stage trial tests a new oral drug, DCC-2812, in about 60 people with advanced kidney, bladder, or prostate cancer that has spread or stopped responding to standard treatments. The main goals are to check safety and find the right dose, while also watching for any tumor shrinkage. Participants must be able to take pills and have adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT Oncology, Austin
RECRUITINGAustin, Texas, 78758, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology, San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt- Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.